Drug intelligence / Profile preview

TEV-56325

Development stage: Preclinical
Lead developer: Teva Pharmaceutical

Overview

TEV-56325 (also identified as TEV-325) is a preclinical drug candidate currently under development by Teva Pharmaceuticals within its immunology pipeline. As of early 2024, the asset is in the early stages of research, and Teva has not yet disclosed its specific molecular target, mechanism of action, or modality (e.g., small molecule or biologic). The drug is being investigated for potential applications in the treatment of various immunological and inflammatory disorders. It represents part of Teva's strategic "Pivot to Growth" initiative, which emphasizes the expansion of its innovative pipeline in core therapeutic areas such as immunology and neuroscience.

Beyond the preview

Go deeper on TEV-56325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-56325.

Explore the full profile